Form 4: Alnylam CEO Exercises Options, Adjusts Holdings

Alnylam Pharmaceuticals CEO Yvonne Greenstreet reported exercising multiple stock options and a subsequent disposition of shares on November 26, 2025, adjusting her beneficial ownership.

Summary

• Yvonne Greenstreet, Chief Executive Officer and Director of Alnylam Pharmaceuticals, Inc. (ALNY), reported several transactions on November 26, 2025.
• Exercised stock options to acquire 839 shares of common stock at an exercise price of $119.13 per share.
• Exercised stock options to acquire 2,352 shares of common stock at an exercise price of $85 per share.
• Exercised stock options to acquire 847 shares of common stock at an exercise price of $118.05 per share.
• Exercised stock options to acquire 659 shares of common stock at an exercise price of $151.59 per share.
• Disposed of 1,121 shares of common stock at a price of $445.12 per share, likely to cover tax withholding obligations related to the option exercises.
• Acquired 407 shares of ALNY common stock indirectly through the issuer's 401(k) plan as a result of the 401(k) matching contribution program.
• Following these transactions, beneficial ownership stands at 68,985 shares held directly and 407 shares held indirectly through a managed account.

Sentiment

Score: 6

Explanation: The filing reports routine insider transactions involving the exercise of vested stock options and a subsequent disposition of shares, likely for tax purposes. This is generally a neutral event, but the exercise of options can be seen as a positive signal of an executive realizing value from their equity.

Positives

• The CEO exercised a significant number of vested stock options, indicating a realization of value from her equity compensation.
• Acquisition of shares through the company's 401(k) matching program demonstrates continued participation in employee benefits.

Negatives

• Disposition of 1,121 shares, although likely for tax purposes, reduces direct beneficial ownership.

Future Outlook

NA

Industry Context

NA

Related Party Transactions

• Acquisition of 407 shares of ALNY common stock by the Reporting Person under the issuer's 401(k) plan as a result of the issuer's 401(k) matching contribution program.
• Exercise of stock options granted by the issuer to the Reporting Person as part of her compensation.

Stakeholder Impact

• Shareholders: Provides transparency regarding the equity transactions of a key executive, which is standard for corporate governance.
• Employees: Demonstrates the utilization of standard equity compensation and retirement benefits by a senior executive.

Key Dates

Recommendation

The Form 4 details routine insider transactions by the CEO, Yvonne Greenstreet, involving the exercise of vested stock options and a subsequent disposition of shares, likely for tax purposes. These transactions are part of standard executive compensation and equity management and do not inherently signal a change in the company's fundamental outlook or warrant a shift in investment recommendation. Therefore, a 'hold' recommendation is appropriate as these actions are neutral in terms of investment implications.

Keywords

Alnylam Pharmaceuticals, ALNY, Form 4, Insider Transaction, Stock Options, Yvonne Greenstreet, CEO, Beneficial Ownership